Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E (including its water-soluble form, tocofersolan) has been investigated for its potential in reducing certain chemotherapy-induced side effects, particularly chemotherapy-induced peripheral neuropathy (CIPN) and oral mucositis. The rationale is based on Vitamin E’s antioxidant properties, which may help protect healthy cells from the oxidative stress and free radical damage caused by some chemotherapeutic agents.

Several small clinical trials and meta-analyses have explored Vitamin E supplementation during chemotherapy. Some studies have shown a reduction in the severity or incidence of CIPN, particularly with platinum-based drugs (like cisplatin), when Vitamin E is administered. However, results are inconsistent, with some trials showing modest benefits and others showing no significant effect. A few meta-analyses have suggested a possible protective effect, but have also noted methodological limitations, small sample sizes, and heterogeneity among studies.

Importantly, concerns remain about the potential for antioxidants like Vitamin E to reduce the efficacy of chemotherapy by protecting cancer cells as well as healthy tissue. Current oncology guidelines generally do not recommend routine antioxidant supplementation during chemotherapy due to these uncertainties.

In summary, while there is some scientific investigation into the use of Vitamin E (including tocofersolan) for reducing certain chemotherapy side effects, the evidence is limited and not sufficiently robust to support routine use. Larger and more rigorous studies are needed to clarify its safety and efficacy in this context.

More about Vitamin E (tocofersolan)
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by Vitamin E (tocofersolan)

Products containing Vitamin E (tocofersolan)